| 摘要 |
The present invention provides two gene expression signatures indicative of poor prognosis for lung cancer subjects, preferably in NSCLC, more preferably stage I NSCLC, and even more preferably stage I lung adenocarcinoma. These signatures were found to be very efficient to predict patient's outcome. Thus, they allow the practitioner to accurately distinguish lung tumors associated with poor prognosis so as to target the patients who would really benefit from adjuvant therapy and spare unnecessary treatment to patients with a good prognosis, preferably in NSCLC, more preferably stage I NSCLC, and even more preferably stage I lung adenocarcinoma. |
